MSMartin A. Sieber

Martin A. Sieber

*This is an algorithmically generated author record based on publicly available information.

Martin A. Sieber has a total of 81 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Azelaic Acid: Properties and Mode of Action

    by M.A. Sieber, J.K.E. Hegel

    Acne is a common skin disorder that can be problematic for adults as well as for adolescents. It has several key pathophysiological features such as follicular hyperkeratosis, elevated Propionibacterium acnes proliferation, and reactive inflammation, all of which should be targeted for an optimal outcome. Azelaic acid (AzA) has profound anti-inflammatory, antioxidative effects, and is bactericidal against a range of Gram-negative and Gram-positive microorganisms as well, including antibiotic-resistant bacterial strains. In addition, AzA's antikeratinizing effects are inhibitory toward comedones. AzA is effective overall in targeting multiple causes of acne and has been proven to be well tolerated in numerous clinical trials.


  • Reactive oxygen species and the bacteriostatic and bactericidal effects of isoconazole nitrate

    by Viktor A. Czaika, Jan Siebenbrock, Frank Czekalla, Torsten Zuberbier, Martin A. Sieber

    Bacterial superinfections often occur in dermatomycoses, resulting in greatly inflamed or eczematous skin. The objective of this study was to evaluate the antibacterial efficacy of isoconazole nitrate (ISN), a broad‐spectrum antimicrobial imidazole, commonly used to treat dermatomycoses. Several gram‐positive bacteria minimal inhibitory concentrations (MICs) for ISN (ISN solution or ISN‐containing creams: Travogen® or corticosteroid‐containing Travocort®) and ampicillin were obtained using the broth‐dilution method. Speed of onset of the bactericidal effect was determined with bacterial killing curves. Reactive oxygen species (ROS) were visualised by staining cells with singlet oxygen detector stain. Compared with ampicillin MICs, ISN MICs for Bacillus cereus, Staphylococcus haemolyticus and Staphylococcus hominis were lower and ISN MICs for Corynebacterium tuberculostearicum and Streptococcus salivarius were similar. Incubation with ISN led to a 50% kill rate for Staphylococcus aureus and methicillin‐resistant strains (MRSA). Post‐ISN incubation, 36% (30 min) and 90% (60 min) of S. aureus cells were positive for ROS. Isoconazole nitrate has a broad bacteriostatic and bactericidal action, also against a MRSA strain that was not reduced by the corticosteroid in the Travocort cream. Data suggest that the antibacterial effect of ISN may be ROS dependent. An antifungal agent with robust antibacterial activity can provide a therapeutic advantage in treating dermatomycoses with suspected bacterial superinfections.


  • The Osmolality of Nonionic, Iodinated Contrast Agents as an Important Factor for Renal Safety

    by Diana C. Lenhard, Hubertus Pietsch, Martin A. Sieber, Rainer Ernst, Philipp Lengsfeld, Peter Ellinghaus, Gregor Jost

    Nonionic iodinated contrast agents (CAs) can be divided into monomeric, low-osmolar, and dimeric, iso-osmolar classes. In clinical practice, renal tolerance of CAs is a concern, especially in patients with impaired renal function. With regard to renal safety, we wanted to evaluate the role of osmolality and viscosity in renal tolerance. We generated a formulation (iodixanol/mannitol) consisting of the dimeric iodixanol with an osmolality of the monomeric iopromide. Male Han-Wistar rats were intravenously injected with low-osmolar iopromide 300, iso-osmolar iodixanol 320, and iodixanol/mannitol. Saline and diatrizoate were used as controls. A total number of 227 rats were used in the following experiments. We compared the impact of osmolality on renal iodine retention using computed tomography 2 and 24 hours postinjection (p.i.). The animals were killed 2, 24, and 72 hours after injection, and the kidneys were excised for further investigations. Changes in renal cell proliferation were analyzed by 5-bromo-2'-deoxyuridine incorporation 48 hours p.i. as a degree of tissue regeneration after induced injury. To specify potential renal injury, we quantified the expression of acute kidney injury (AKI) markers (kidney injury marker-1 [KIM-1], neutrophil gelatinase-associated lipocalin [NGAL], and plasminogen activator inhibitor-1 [PAI-1]) by quantitative real-time polymerase chain reaction. Furthermore, the kidneys were analyzed histologically, including immunofluorescence analysis. After intravenous application of the CAs into Han-Wistar rats, renal iodine concentration was increased (3-fold) for iodixanol 2 hours p.i. and iodine retention was detected to be prolonged 24 hours p.i. compared with iopromide injection (iodixanol, 520 ± 50 Hounsfield Units [HU] vs iopromide, 42 ± 5 HU). The higher iodine concentration 2 hours p.i. upon iodixanol injection was reduced almost to the level of iopromide when injecting iodixanol/mannitol (iopromide: 289 ± 68 HU vs iodixanol/mannitol: 343 ± 68 HU). In addition, iodixanol application induced increased renal cell proliferation (2.7-fold vs saline), indicating renal injury, which was significantly lower in iopromide-treated animals (1.6-fold vs saline). More detailed analysis of markers for AKI revealed that iodixanol significantly induced the expression of PAI-1 (7.7-fold at 2 hours) as well as KIM-1 (2.1-fold) and NGAL (3.2-fold) at 2 and 24 hours when compared with saline treatment. In contrast, the expression of markers for AKI was low after iopromide (1.4-fold NGAL, 1.7-fold PAI-1, KIM-1 not significant) and iodixanol/mannitol (1.6-fold NGAL, 2.6-fold PAI-1, KIM-1 not significant) injection. The present results clearly show that prolonged iodine retention and the enhanced expression of kidney injury markers are caused mainly by the explicitly higher urine viscosity induced by iodixanol. We conclude that the osmolality of low-osmolar CAs such as iopromide induces a positive diuretic effect that is responsible for rapid iodine clearance and prevents increased expression of acute injury markers in the kidney.


  • MicroRNA and Messenger RNA Analyses of Mesenchymal Stem Cells Derived from Teeth and the Wharton Jelly of Umbilical Cord

    by Hua-Chien Chen, Yun-Shien Lee, Martin Sieber, Huan-Ting Lu, Pei-Cih Wei, Chao-Nin Wang, Hsiu-Huei Peng, An-Shine Chao, Po-Jen Cheng, Shuenn-Dyh Chang, et al.

    Microarray analyses of transcriptomes have been used to characterize mesenchymal stem cells (MSCs) of various origins. MicroRNAs (miRNAs) are short, nonprotein-coding RNAs involved in post-transcriptional gene inhibition in a variety of tissues, including cancer cells and MSCs. This study has integrated the use of miRNA and mRNA expression profiles to analyze human MSCs derived from Wharton's jelly (WJ) of the umbilical cord, milk teeth (MT), and adult wisdom teeth (AT). Because both miRNA and mRNA expression in MT and AT MSCs were so similar, they were combined together as tooth MSCs for comparison with WJ MSCs. Twenty-five genes that were up-regulated in tooth MSCs and 41 genes that were up-regulated in WJ MSCs were identified by cross-correlating miRNA and mRNA profiles. Functional network analysis show that tooth MSCs signature genes, represented by SATB2 and TNFRSF11B, are involved in ossification, bone development, and actin cytoskeleton organization. In addition, 2 upregulated genes of tooth MSCs—NEDD4 and EMP1—have been shown to be involved in neuroectodermal differentiation. The signature genes of WJ MSCs, represented by KAL1 and PAPPA, are involved in tissue development, regulation of cell differentiation, and bone morphogenetic protein signaling pathways. In conclusion, the combined interrogation of miRNA and mRNA expression profiles in this study proved useful in extracting reliable results from a genome-wide comparison of multiple types of MSCs. Subsequent functional network analysis provided further functional insights about these MSCs.


  • Efficacy and safety of lanthanoids as X-ray contrast agents

    by Hubertus Pietsch, Gregor Jost, Thomas Frenzel, Marian Raschke, Jakob Walter, Heiko Schirmer, Joachim Hütter, Martin A. Sieber


  • Viscosity of iodinated contrast agents during renal excretion

    by Gregor Jost, Philipp Lengsfeld, Diana C. Lenhard, Hubertus Pietsch, Joachim Hütter, Martin A. Sieber


  • The Role of Residual Gadolinium in the Induction of Nephrogenic Systemic Fibrosis-Like Skin Lesions in Rats

    by Hubertus Pietsch, Marian Raschke, Heidrun Ellinger-Ziegelbauer, Gregor Jost, Jakob Walter, Thomas Frenzel, Diana Lenhard, Joachim Hütter, Martin A. Sieber

    Nephrogenic systemic fibrosis (NSF) is an acquired, idiopathic disorder. Most of the cases are observed in patients with end stage renal disease (ESRD). The objective of this nonclinical animal study was to test the hypothesis that gadolinium (Gd) deposits play a role in the induction of NSF lesions. In addition, we evaluated whether an acute response to Gd exposure can initiate a process that results in fibrosis of the skin. Han-Wistar rats were administered 3 intravenous injections of Gd-DTPA-BMA formulated without Gd-free excess ligand (Gadodiamide without Caldiamide) at a dose of 2.5 mmol/kg of body weight (b.w.) per injection given at 24-hour or 14-, 28-, or 56-day intervals. The occurrence and development of NSF-like fibrosing dermopathy lesions were followed. The Gd concentration was determined by Inductively Coupled Plasma Mass Spectrometry in skin biopsies taken during the study and organ samples taken at the end of the study.In a separate study, after injection of a single intravenous dose of 2.5 mmol/kg b.w. Gd-DTPA-BMA administered to Han-Wistar rats, the expression of cytokines and signaling molecules in serum and skin tissue was determined by quantitative RT-PCR and Luminex technology 6 hours or 14, 28, or 56 days. The occurrence of NSF-like macroscopic skin lesions differed between the injection groups. Shorter injection intervals resulted in more severe skin reactions. In contrast, the injection interval did not influence the long-term presence and level of accumulation of Gd concentration in tissue. The single injection of Gd-DTPA-BMA was followed by a rapid and transient induction of signaling molecules in the serum (MCP1, MCP3, IL1, IP-10, Osteopontine SCF and Timp1) as well as in the skin (MCP1 and TGFb). The presence of NSF-like fibrosing dermopathy in rats was found to be dependent on the injection interval and not on the amount of Gd in tissue. Our findings suggest the possibility of a more acute intrinsic reaction on administration of Gd-DTPA-BMA that triggers events leading to the development of skin lesions. The finding that single injections of Gd-DTPA-BMA were accompanied by a fast and transient induction of signaling molecules that are known to be involved in several fibrotic events provides additional support for this hypothesis. The study findings, however, do not support the theory that the long-term presence of Gd plays a relevant role in the development of NSF.


  • A Review of Preclinical Safety Data for Magnevist (Gadopentetate Dimeglumine) in the Context of Nephrogenic Systemic Fibrosis

    by Thomas Steger-Hartmann, Rainer Hofmeister, Rainer Ernst, Hubertus Pietsch, Martin A. Sieber, Jacob Walter

    Magnevist (gadopentetate dimeglumine, Bayer Healthcare, Bayer) is a gadolinium-based contrast agent (GBCA) for magnetic resonance imaging approved for clinical use in various indications since 1988. A possible association between the administration of GBCAs to patients with severe kidney impairment, and a condition first identified in 2000 and later described as "nephrogenic systemic fibrosis" (NSF), was published in early 2006. In the light of this reported association and the published histologic findings of certain NSF patients, Bayer, with support of external experts, reassessed the preclinical safety data from in vivo studies in healthy rats and dogs that were conducted with Magnevist during the drug development process in the mid-80s. These studies, which were performed according to standard regulatory requirements as defined in pertinent guidelines and which were conducted before the reported association between GBCAs and NSF, were not specifically designed to detect NSF-like lesions. Instead, the intention of this reassessment was to analyze whether the acquired knowledge on NSF would lead to a revised interpretation of the original preclinical data. Studies on repeat-dose toxicity of Magnevist performed in the mid-80s with healthy rats and dogs were re-evaluated, with special emphasis on the retrospective analysis of morphologic findings which have come to be considered potentially suggestive of NSF. In particular, histologic slides of the skin of repeat-dose toxicity studies were re-examined by Bayer pathologists, with a special focus on the occurrence of morphologic lesions that have subsequently been identified as consistent with NSF. In addition, slides from selected studies were also subjected to a blinded external peer review by an independent international Pathology Working Group. A review of the preclinical data from the repeated-dose toxicity studies provided no evidence for toxicological effects after administration of Magnevist, which could be construed as suggestive of or consistent with NSF. More specifically, histopathology peer reviews of skin samples from repeated-dose toxicity studies with rats and dogs revealed no signs of skin lesions even after repeated high-dose administration to rats of 5.0 mmol Gd/kg of Magnevist (50 times the standard diagnostic dose). No findings were observed in any of the preclinical studies with Magnevist in healthy rats and dogs which could be characterized as similar to the types of morphologic lesions that have subsequently been identified as consistent with NSF. This preclinical assessment is in contrast to the reported clinical evidence of rare NSF cases in patients with severe kidney impairment after Magnevist administration. The differences between the preclinical models and their predictive limitations with regard to the clinical situation of renally impaired patients are discussed.


  • The Impact of the Viscosity and Osmolality of Iodine Contrast Agents on Renal Elimination

    by Gregor Jost, Hubertus Pietsch, Philipp Lengsfeld, Joachim Hütter, Martin A. Sieber

    The iodinated contrast agents (CAs) that are currently used in radiographic procedures possess special physicochemical properties and a high safety profile; however, according to a large retrospective study (Swedish registry), the viscosity of CAs may have an underestimated impact on renal failure. The aim of our study was to investigate the possible consequences of CA viscosity differences, such as CA retention in the kidney. Five Göttingen minipigs were each intravenously injected in a crossover setting at intervals of at least 7 days with monomeric (Iopromide) and dimeric (Iodixanol) CAs at 2 doses (1 and 2 g iodine/kg bodyweight), and the retention of the CA in the kidneys was determined during the first 6 hours postinjection using a 64-slice computed tomography scanner. Additionally we performed in vitro dialysis of the monomeric and dimeric CAs across the various physiological osmolalities of the renal tubulus (300, 600, 800, and 1200 mOsm/kg H(2)O) to estimate CA viscosity in vivo. Following the dialyzes, iodine concentrations and CA viscosities were determined. A different exposure of the kidneys to iodine and a different elimination kinetics from the kidneys was observed after the administration of monomeric and dimeric CAs. The monomeric agent was observed to clear from the kidney immediately after administration. In contrast, after administration of the dimeric CA an increase in iodine concentration in the kidney was observed up to 180 minutes postinjection, before the CA was observed to begin clearing; however, no difference was observed between the plasma half-lives of the 2 investigated CAs. In vitro dialysis of the dimeric CA increased iodine concentrations and strongly increased viscosity at all of the tested osmolalities. In contrast, the monomeric agent only demonstrated increases in iodine concentration and viscosity at 800 and 1200 mOsm/kg, and these changes were smaller than those observed for the dimeric CA. In summary, dialysis strongly enhanced the viscosity differences between the 2 investigated CAs. The viscosity differences between the investigated monomeric and dimeric CAs are strongly enhanced by concentration processes, such as the process taking place in the tubular system. These viscosity differences may be the cause of the prolonged retention and the different elimination kinetics from the kidney observed after application of the dimeric CA relative to the monomeric CA.